These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35223258)

  • 1. Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge.
    Griffith P; Jedrych J; Sunshine J; Laheru DA; Yarchoan M
    Cureus; 2022 Jan; 14(1):e21478. PubMed ID: 35223258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management and mechanism of calciphylaxis in a patient treated with the FGFR inhibitor pemigatinib-a case report.
    Chandana SR; Frisch A; Mendoza S; Sinniah RS; Crysler O; Banga R; Perkins DE
    J Gastrointest Oncol; 2024 Feb; 15(1):478-484. PubMed ID: 38482230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use.
    Puar A; Donegan D; Helft P; Kuhar M; Webster J; Rao M; Econs M
    AACE Clin Case Rep; 2022; 8(5):217-220. PubMed ID: 36189136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion.
    Storandt MH; Jin Z; Mahipal A
    Expert Rev Anticancer Ther; 2022 Dec; 22(12):1265-1274. PubMed ID: 36408971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.
    Kommalapati A; Tella SH; Borad M; Javle M; Mahipal A
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
    Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
    Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
    Weaver A; Bossaer JB
    J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
    Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
    Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.
    Arudra K; Patel R; Tetzlaff MT; Hymes S; Subbiah V; Meric-Bernstam F; Torres-Cabala C; Aung PP; Nagarajan P; Diab A; Prieto VG; Nelson K; Curry JL
    J Cutan Pathol; 2018 Oct; 45(10):786-790. PubMed ID: 30021048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements.
    Walden D; Eslinger C; Bekaii-Saab T
    Therap Adv Gastroenterol; 2022; 15():17562848221115317. PubMed ID: 35967919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
    Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N
    Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting FGFRs Using PD173074 as a Novel Therapeutic Strategy in Cholangiocarcinoma.
    Balasubramanian B; Yacqub-Usman K; Venkatraman S; Myint KZ; Juengsamarn J; Sarkhampee P; Lertsawatvicha N; Sripa J; Kuakpaetoon T; Suriyonplengsaeng C; Wongprasert K; Grabowska AM; Bates DO; Janvilisri T; Tohtong R
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
    Aitcheson G; Mahipal A; John BV
    Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinicogenomic Analysis of
    Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
    Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
    Merz V; Zecchetto C; Melisi D
    Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
    Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
    J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postpartum related intrahepatic cholangiocarcinoma with
    Washburn L; Mahipal A; Jatoi A; Kottschade L; Tran N
    J Gastrointest Oncol; 2023 Dec; 14(6):2627-2636. PubMed ID: 38196530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.